The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.

Patients with PsA who are treated with CTT are not at a greater risk for serious or opportunistic infections compared with standard therapy.

Results of a meta-analysis showed that a history of allergies, multiorgan involvement, and decreased complement levels were linked to higher risk for IgG4-RD relapse.

Both medication-based and surgical weight loss interventions were linked to lower rates of obesity-related cancers in people with obesity and T2D.

Adults with vs without chronic back pain have a higher prevalence of noncommunicable diseases and comorbidities.

Eugene Declercq, Ph.D., from Boston University in Massachusetts, and colleagues conducted a retrospective cohort study to examine the association between pregnancy-associated death or severe maternal ...

In recognition of World Arthritis Day 2025, we spoke with experts on the role of providers in enhancing care and ...

Women with nr-axSpA — but not r-axSpA — were less likely than men to achieve low disease activity/inactive disease status at 1 year.

Rheumatology Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...

The FDA may change the warning label on HRT drugs for menopause symptoms to reflect improved safety data and increase use.

Costco will sell a 4-week supply of Ozempic or Wegovy for $499 out-of-pocket for customers with a valid prescription.

The μFRAC tool showed promise for monitoring fracture risk over time in response to bone changes in aging adults.